JPMorgan Chase & Co. Sells 7,591 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

JPMorgan Chase & Co. reduced its position in Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 566,130 shares of the company’s stock after selling 7,591 shares during the period. JPMorgan Chase & Co. owned 0.62% of Myriad Genetics worth $15,506,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Loomis Sayles & Co. L P grew its holdings in Myriad Genetics by 153.7% during the 3rd quarter. Loomis Sayles & Co. L P now owns 2,189,601 shares of the company’s stock valued at $59,973,000 after buying an additional 1,326,497 shares in the last quarter. Disciplined Growth Investors Inc. MN grew its holdings in Myriad Genetics by 21.1% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock valued at $69,226,000 after buying an additional 440,107 shares in the last quarter. Iron Triangle Partners LP purchased a new position in Myriad Genetics during the 3rd quarter valued at about $11,007,000. State Street Corp grew its holdings in Myriad Genetics by 8.3% during the 3rd quarter. State Street Corp now owns 4,703,442 shares of the company’s stock valued at $128,827,000 after buying an additional 359,685 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Myriad Genetics by 26.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,063,711 shares of the company’s stock valued at $29,135,000 after buying an additional 224,255 shares in the last quarter. 99.02% of the stock is currently owned by institutional investors.

Myriad Genetics Trading Up 0.3 %

Myriad Genetics stock opened at $14.83 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. Myriad Genetics, Inc. has a one year low of $12.87 and a one year high of $29.30. The stock has a market capitalization of $1.35 billion, a PE ratio of -11.41 and a beta of 1.89. The business’s fifty day moving average is $15.19 and its 200 day moving average is $22.35.

Analyst Upgrades and Downgrades

MYGN has been the subject of a number of recent analyst reports. Piper Sandler reduced their target price on Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, November 11th. UBS Group assumed coverage on Myriad Genetics in a report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price objective for the company. Leerink Partners lowered Myriad Genetics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $30.00 to $21.00 in a report on Monday, December 9th. Morgan Stanley cut their price objective on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, November 18th. Finally, StockNews.com raised Myriad Genetics from a “hold” rating to a “buy” rating in a report on Thursday. Three research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $24.27.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.